HLB said the company would present the two interim results of combination treatment of its rivoceranib with immune-oncology and cytotoxic antineoplastic drugs at the online World Conference on Lung Cancer (WCLC) 2021 on Sept. 13.

The clinical results showed a 40 percent overall response rate (ORR), 92 percent disease control rate (DCR), and 11 months of a median progression-free survival (mPFS), demonstrating high efficacy and safety as a first-line treatment for advanced non-small-cell lung cancer (NSCLC).

The presentation will be based on phase 2 clinical trial results of rivoceranib, marketed as Apatinib in China, and camrelizumab, a programmed cell death 1 (PD-1) inhibitor in 25 NSCLC patients at a hospital specialized in lung cancer in Shanghai, China.

The company will also unveil the combination therapy results of rivoceranib, camrelizumab, and the albumin-bound paclitaxel in patients with advanced NSCLC through posters.

A phase 2 study conducted on eight patients with stage three to four NSCLC at a lung cancer hospital in Hunan Province, China, showed stable efficacy with 50 percent ORR and 62.5 percent DCR.

On Tuesday, results of triple combo therapy of rivoceranib, albumin-bound paclitaxel, and carboplatin as neoadjuvant therapy for 32 triple-negative breast cancer (TNBC) patients at the First Affiliated Hospital of Nanjing Medical University in China were published at a preprint platform Research Square.

During the study, complete remission was observed in seven patients who underwent a surgical operation, 23 patients showed partial remission, and two patients had stable disease.

Researchers suggested that pre-treatment of the three drugs could be effective in TNBC patients who have difficultly receiving surgery immediately due to their tumor size.

WCLC is the world's largest academic conference specializing in lung cancer and other thoracic malignancy, drawing about 7,000 participants from more than 100 countries every year.